These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 25572023)

  • 1. One-year outcomes in unselected patients treated with a thin-strut, platinum-chromium, paclitaxel-eluting stent: primary endpoint results from the TAXUS Element European post-approval surveillance study (TE-PROVE).
    Tamburino C; Capodanno D; Erglis A; Menown IB; Horváth IG; Moreno R; Gilbert TJ; Crowley JJ; Calabria P; Allocco DJ; Dawkins KD
    EuroIntervention; 2015 Mar; 10(11):1261-6. PubMed ID: 25572023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. One-year outcomes in 1,010 unselected patients treated with the PROMUS Element everolimus-eluting stent: the multicentre PROMUS Element European Post-Approval Surveillance Study.
    Thomas MR; Birkemeyer R; Schwimmbeck P; Legrand V; Moreno R; Briguori C; Werner N; Bramucci E; Ungi I; Richardt G; Underwood PL; Dawkins KD
    EuroIntervention; 2015 Mar; 10(11):1267-71. PubMed ID: 25631367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and angiographic outcomes after treatment of de novo coronary stenoses with a novel platinum chromium thin-strut stent: primary results of the PERSEUS (Prospective Evaluation in a Randomized Trial of the Safety and Efficacy of the Use of the TAXUS Element Paclitaxel-Eluting Coronary Stent System) trial.
    Kereiakes DJ; Cannon LA; Feldman RL; Popma JJ; Magorien R; Whitbourn R; Dauber IM; Rabinowitz AC; Ball MW; Bertolet B; Kabour A; Foster MC; Wang JC; Underwood P; Dawkins KD
    J Am Coll Cardiol; 2010 Jul; 56(4):264-71. PubMed ID: 20493653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical outcomes following implantation of the ION™ paclitaxel-eluting platinum chromium coronary stent in routine clinical practice: Results of the ION U.S. post-approval study.
    Cannon LA; Kimmelstiel CD; White A; Hill R; Grady TP; Myers PR; Underwood P; Dawkins KD
    Catheter Cardiovasc Interv; 2019 Sep; 94(3):334-341. PubMed ID: 30597737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical outcomes in unselected patients treated with the PROMUS Element platinum-chromium, everolimus-eluting stent: Final five-year results from the PE PROVE Study.
    Moreno R; Legrand V; Ferrario M; MacCarthy P; Redwood S; Werner N; Jung W; Ungi I; Zaman A; Richardt G; Crowley J; Schwimmbeck P; Christen T; Allocco DJ; Meredith IT
    Catheter Cardiovasc Interv; 2019 Feb; 93(3):398-403. PubMed ID: 30341836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term follow-up of the platinum chromium TAXUS Element (ION) stent: The PERSEUS Workhorse and Small Vessel trial five-year results.
    Kereiakes DJ; Cannon LA; Dauber I; Ball M; Bertolet B; Foster M; Nersesov AY; Underwood PL; Allocco DJ; Dawkins KD
    Catheter Cardiovasc Interv; 2015 Nov; 86(6):994-1001. PubMed ID: 25678402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 5-year results of a randomized comparison of XIENCE V everolimus-eluting and TAXUS paclitaxel-eluting stents: final results from the SPIRIT III trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions).
    Gada H; Kirtane AJ; Newman W; Sanz M; Hermiller JB; Mahaffey KW; Cutlip DE; Sudhir K; Hou L; Koo K; Stone GW
    JACC Cardiovasc Interv; 2013 Dec; 6(12):1263-6. PubMed ID: 24239202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. One-year outcomes with the Taxus Liberté stent in the real world: the Taxus Olympia registry (phase I).
    Ahmed WH; Zambahari R; Al-Rashdan I; Al Naeemi A; Saeed FA; Mascioli S
    J Interv Cardiol; 2008 Dec; 21(6):512-8. PubMed ID: 18973513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. One-Year Outcomes in "Real-World" Patients Treated With a Thin-Strut, Platinum-Chromium, Everolimus-Eluting Stent (from the PROMUS Element Plus US Post-Approval Study [PE-Plus PAS]).
    Kandzari DE; Amjadi N; Caputo C; Rowe SK; Williams J; Tamboli HP; Christen T; Allocco DJ; Dawkins KD
    Am J Cardiol; 2016 Feb; 117(4):539-545. PubMed ID: 26732420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PLATINUM China: a prospective, randomized investigation of the platinum chromium everolimus-eluting stent in de novo coronary artery lesions.
    Gao R; Han Y; Yang Y; Zhang J; Hou Y; Wang H; Li H; Fang Q; Yu B; Xu B; Allocco DJ; Dawkins KD
    Catheter Cardiovasc Interv; 2015 Mar; 85 Suppl 1():716-23. PubMed ID: 25631909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two-year safety and effectiveness of the platinum chromium everolimus-eluting stent for the treatment of small vessels and longer lesions.
    Teirstein PS; Meredith IT; Feldman RL; Rabinowitz AC; Cannon LA; Lee TC; Dens J; Dubois CL; Mooney MR; Pompili VJ; Saito S; Allocco DJ; Dawkins KD; Stone GW
    Catheter Cardiovasc Interv; 2015 Feb; 85(2):207-15. PubMed ID: 24905795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Zotarolimus- and paclitaxel-eluting stents in an all-comer population in China: the RESOLUTE China randomized controlled trial.
    Xu B; Yang Y; Yuan Z; Du Z; Wong SC; Généreux P; Lu S;
    JACC Cardiovasc Interv; 2013 Jul; 6(7):664-70. PubMed ID: 23523240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome After Myocardial Infarction Treated With Resolute Integrity and Promus Element Stents: Insights From the DUTCH PEERS (TWENTE II) Randomized Trial.
    van Houwelingen KG; Lam MK; Löwik MM; Danse PW; Tjon Joe Gin RM; Jessurun GA; Anthonio RL; Sen H; Linssen GCM; IJzerman MJ; Doggen CJM; von Birgelen C
    Rev Esp Cardiol (Engl Ed); 2016 Dec; 69(12):1152-1159. PubMed ID: 27595181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unprotected left main stenting in the real world: five-year outcomes of the French Left Main Taxus registry.
    Mylotte D; Meftout B; Moynagh A; Vaquerizo B; Darremont O; Silvestri M; Louvard Y; Leymarie JL; Morice MC; Lefèvre T; Garot P
    EuroIntervention; 2012 Dec; 8(8):970-81. PubMed ID: 23014945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of second-generation drug-eluting stents three years after randomised use in the TWENTE trial.
    Löwik MM; Lam MK; Sen H; Tandjung K; van Houwelingen KG; de Man FH; Stoel MG; Louwerenburg JH; Linssen GC; Doggen CJ; von Birgelen C
    EuroIntervention; 2015 Mar; 10(11):1276-9. PubMed ID: 25136888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY).
    Valgimigli M; Tebaldi M; Borghesi M; Vranckx P; Campo G; Tumscitz C; Cangiano E; Minarelli M; Scalone A; Cavazza C; Marchesini J; Parrinello G;
    JACC Cardiovasc Interv; 2014 Jan; 7(1):20-8. PubMed ID: 24332420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Everolimus-eluting stents versus sirolimus- or paclitaxel-eluting stents: two-year results from the Guthrie Health Off-Label Stent (GHOST) registry.
    Harjai KJ; Kondareddy S; Pinkosky B; Harjai N; Orshaw P; Boura J
    J Interv Cardiol; 2013 Apr; 26(2):153-62. PubMed ID: 23363439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Third-generation zotarolimus-eluting and everolimus-eluting stents in all-comer patients requiring a percutaneous coronary intervention (DUTCH PEERS): a randomised, single-blind, multicentre, non-inferiority trial.
    von Birgelen C; Sen H; Lam MK; Danse PW; Jessurun GA; Hautvast RW; van Houwelingen GK; Schramm AR; Gin RM; Louwerenburg JW; de Man FH; Stoel MG; Löwik MM; Linssen GC; Saïd SA; Nienhuis MB; Verhorst PM; Basalus MW; Doggen CJ; Tandjung K
    Lancet; 2014 Feb; 383(9915):413-23. PubMed ID: 24183564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 4-year clinical outcomes and predictors of repeat revascularization in patients treated with new-generation drug-eluting stents: a report from the RESOLUTE All-Comers trial (A Randomized Comparison of a Zotarolimus-Eluting Stent With an Everolimus-Eluting Stent for Percutaneous Coronary Intervention).
    Taniwaki M; Stefanini GG; Silber S; Richardt G; Vranckx P; Serruys PW; Buszman PE; Kelbaek H; Windecker S;
    J Am Coll Cardiol; 2014 Apr; 63(16):1617-25. PubMed ID: 24530680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A prospective evaluation of the safety and efficacy of the TAXUS Element paclitaxel-eluting coronary stent system for the treatment of de novo coronary artery lesions: design and statistical methods of the PERSEUS clinical program.
    Allocco DJ; Cannon LA; Britt A; Heil JE; Nersesov A; Wehrenberg S; Dawkins KD; Kereiakes DJ
    Trials; 2010 Jan; 11():1. PubMed ID: 20059766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.